Arcus Biosciences financials
$25.65+2.56%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $247.0M | $258.0M | $117.0M | $112.0M | $383.0M | $78.0M | $15.0M | $8.4M |
| Gross profit | $247.0M | $258.0M | $117.0M | $112.0M | $383.0M | $78.0M | $15.0M | $8.4M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$386.0M | -$330.0M | -$340.0M | -$280.0M | $54.0M | -$124.0M | -$88.7M | -$54.9M |
| Net income | -$353.0M | -$283.0M | -$307.0M | -$267.0M | $53.0M | -$123.0M | -$84.7M | -$49.6M |
| Net margin | −142.9% | −109.7% | −262.4% | −238.4% | 13.8% | −157.7% | −564.7% | −593.7% |
| Diluted EPS | $-3.29 | $-3.14 | $-4.15 | $-3.71 | $0.71 | $-2.24 | $-1.93 | $-1.43 |
| EBITDA | -$376.0M | -$300.0M | -$332.0M | -$274.0M | $61.0M | -$120.0M | -$85.1M | -$51.2M |
| Operating cash flow | -$482.0M | -$170.0M | -$306.0M | $438.0M | -$256.0M | $111.0M | -$73.5M | -$43.0M |
| Free cash flow | -$484.0M | -$176.0M | -$330.0M | $432.0M | -$282.0M | $108.0M | -$75.4M | -$46.7M |
| Diluted shares | 107.4M | 90.1M | 74.0M | 72.0M | 74.0M | 54.8M | 43.8M | 34.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $222.0M | $150.0M | $127.0M | $206.0M | $148.0M | $173.4M |
| Short-term investments | $759.0M | $828.0M | $632.0M | $803.0M | $351.0M | $555.2M |
| Total debt | $99.0M | $48.0M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.14B | $1.15B | $1.09B | $1.34B | $1.59B | $772.3M |
| Total liabilities | $508.0M | $665.0M | $633.0M | $688.0M | $750.0M | $270.0M |
| Shareholders' equity | $631.0M | $485.0M | $462.0M | $657.0M | $842.0M | $502.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology